# Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

> **NCT05638594** · PHASE2 · RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 236 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Dalpiciclib
- **DRUG:** Letrozole
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Gonadotropin-releasing hormone agonist

## Key facts

- **NCT ID:** NCT05638594
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-20
- **Primary completion:** 2025-12-10
- **Final completion:** 2027-12-10
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638594, "Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05638594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*